TMCnet News
Gallbladder Cancer - Pipeline Review, H2 2017 - Research and MarketsThe "Gallbladder Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Gallbladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecles, respectively. Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/dhzpfg/gallbladder?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171207006008/en/ |